The Effect Of XNTQ(Xingnaotongqiao) Capsule On Animal Behavior In Schizophrenic Model Test

Schizophrenia(SZ) is a kind of severe mental disorder which always appears abnormality such as knowledge(perception, thought) emotion, will, behavior, mental activity etc. The patient’s clinical manifestations: positive symptoms, delusions, hallucinations, thought disorder, speech disorders and act weird, etc.; Negatives symptoms: low motivation, emotion, apathy, poverty of thought, language barrier, will decline, the lack of the social activity. Some patients have both complex and varied symptoms. Now, there are two classes of anti-schizophrenia drugs: the first generation including chlorpromazine, chlorprothixene, haloperidol, sulpiride etc. which mainly control the positive symptoms, but cause typical extrapyramidal system side reactions; the second generation including: risperidone, olazapine, fluorine, aripiprazole etc. which called as an atypical anti-schizophrenia drugs. They have less extrapyramidal reactions than the first generation, and have a good therapeutic effect on both positive symptoms and negative symptoms. Traditional Chinese medicine in the treatment of schizophrenia has its distinct advantage. Xing Nao Tong Qiao(XNTQ) capsule have more than 10 kinds of medicinal materials of traditional Chinese medicine including: buffalo horn, wild bezoar, musk, polygala, cinnabar and so on. This medicine used in the treatment of heat symptoms caused by an exopathgen from heart, barriers of mind, the spirit blocked inducing the epilepsy, mania and schizophrenia. XNTQ combination acupuncture and moxibustion therapy have a good effect on antischizophrenia. To examines the effect of XNTQ on the anti-depressive, anti-anxiety and antischizophrenia activitiy, we selected some pharmacological animal experiments model to observe the antischizophrenia function of XNTQ for forward clinical trials.Objective: To study the Chinese herbal medicine XNTQ capsule on mice and rats behavior in schizophrenic model test.Methods:1 Forty KM mice divided into 4 groups: control group(CMC-Na), XNTQ low dosage group(53mg/kg), XNTQ middle dosage group(160mg/kg), XNTQ high dosage group(480mg/kg). All animals were administered orally according to the body weight, once per day for a week. After one hour since the last administration to detect the percentage rate of sleeping animal.2 Selecting 50 KM mice from 70 number divided into 5 groups: control group(CMC-Na), ASW(Anshenwan) 4.0g/kg XNTQ low dosage group(53mg/kg), XNTQ middle dosage group(160mg/kg), XNTQ high dosage group(480mg/kg). All animals were administered orally according to the body weight, once per day for a week. After one hour since the last administration to detect the parameter, such as animal activity total route, activity time, the ratio of centre area and circum, in open field test and elevated plus maze test.3 Sixty KM mice divided into 5 groups: control group(CMC-Na), Fluoxertine hydrochloride group(30mg/kg), XNTQ low dosage group(53mg/kg), XNTQ middle dosage group(160mg/kg), XNTQ high dosage group(480mg/kg). All animals were administered orally according to the body weight, once per day for a week. After 1-2 hours since the last administration to detect the percentage rate of immobility-time in suspending tail test and forced swimming test(FST).4 Seventy-two KM mice divided into 6 groups: control group(CMC-Na), model group(CMC-Na), Clozapine group(8mg/kg), XNTQ low dosage group(53mg/kg), XNTQ middle dosage group(160mg/kg), XNTQ high dosage group(480mg/kg). All animals were administered orally according to the body weight, once per day for a week. After 1-2 hours since the last administration, all animals except for control group were treated with intraperitoneal injection MK-801(0.6mg/kg). During 4 hours since the last administration to observe the hyperlocomotion, stereotypy behavior and the rate of swimming immobility-time.5 Sixty SD rats divided into 6 groups. All animals except control group were pretreated with intraperitoneal injection ketamine(30mg) for 6 days and then administered orally following these groups: control group(CMC-Na), model group(CMC-Na), XNTQ low dosage group(53mg/kg), XNTQ middle dosage group(160mg/kg), XNTQ high dosage group(480mg/kg), once per day for a week. After 1-2 hours since the last administration, to detect the rate of swimming immobility-time and social interaction ability.Results:1 XNTQ capsule, using the dosage 53, 160, 480 mg/kg, could relieve the animals anxious and nervous behaviors in open field test and elevated plus maze test.2 XNTQ capsule, using the dosage 480 mg/kg, could decrease the percentage rate of immobility-time which reflected the depressed emotion as an indicator in forced swimming test.3 XNTQ capsule, using the dosage 53, 160, 480 mg/kg, could relieve the positive symptoms of schizophrenia mice model, including hyperlocomotion and stereotypy behavior in open field test, and negative symptoms the percentage rate of immobility-time in forced swimming test.4 XNTQ capsule, using the dosage 80, 160 mg/kg, could relieve the negative symptoms of schizophrenia rats model, including decrease the percentage rate of immobility-time in forced swimming test, and could reduce the aggressive behavior in social interaction test, using the dosage 40 mg/kg.Conclusion:All animal behavior tests about XNTQ capsule shows good effects on antianxiety, anti-schizophrenia, anti-depression, in the dose range from 0.5 to 3 times of presupposed clinical dosage(mice reference dosage 160mg/kg, rats 80mg/kg).